Phase 3 Trial Confirms Efficacy of Anifrolumab for Lupus Patients
A recent phase 3 trial has demonstrated that subcutaneous anifrolumab (Saphnelo) offers significant treatment benefits for patients with systemic lupus erythematosus (SLE) when combined with standard therapy. The findings from…